A NEW ERA OF FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITION IN CHOLANGIOCARCINOMA

被引：2
|
作者：
Lamarca, A. [1 ,2 ]
Moreno, V. [3 ]
Gambardella, V. [4 ,5 ]
Cervantes, A. [4 ,5 ]
机构：
[1] Fdn Jimenez Diaz Univ Hosp, Oncohealth Inst, Dept Med Oncol, Madrid, Spain
[2] Christie NHS Fdn Trust, Dept Med Oncol, Manchester, England
[3] Fdn Jimenez Diaz Univ Hosp, Dept Med Oncol, START FJD Phase Unit 1, Madrid, Spain
[4] Univ Valencia, Hosp Clin Univ, INCLIVA Biomed Res Inst, Valencia, Spain
[5] Inst Salud Carlos III, CIBERONC, Madrid, Spain
来源：
ESMO OPEN | 2023年 / 8卷 / 06期
关键词：
METASTATIC CHOLANGIOCARCINOMA; OPEN-LABEL; MULTICENTER; EFFICACY;
D O I：
10.1016/j.esmoop.2023.102032
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [1] Resistance mechanism to fibroblast growth factor receptor (FGFR) inhibitors in cholangiocarcinoma
    Lamarca, Angela
    Ostios, Lorena
    Mcnamara, Mairead G.
    Garzon, Carlos
    Gleeson, Jack P.
    Edeline, Julien
    Herrero, Ana
    Hubner, Richard A.
    Moreno, Victor
    Valle, Juan W.
    CANCER TREATMENT REVIEWS, 2023, 121
  • [2] Cataracts Associated With Fibroblast Growth Factor Receptor Inhibitors for Cholangiocarcinoma
    Kassaye, Isabell
    Alyafaie, Adam
    Zhang, Karen
    Lifton, Jacob
    Gordan, John D.
    Kelley, Robin Kate
    Yung, Madeline
    JAMA OPHTHALMOLOGY, 2024, 142 (12) : 1109 - 1113
  • [3] The future of fibroblast growth factor receptor inhibitors and mechanisms of resistance for cholangiocarcinoma
    Ruff, Samantha M.
    Roychowdhury, Sameek
    Pawlik, Timothy M.
    EXPERT OPINION ON PHARMACOTHERAPY, 2023, 24 (07) : 779 - 788
  • [4] Durable response from fibroblast growth factor receptor inhibition in intrahepatic cholangiocarcinoma terminated by metachronous acute myeloid leukemia: a case report
    Juarso, Andreas Edwin
    Entz, Stefanie
    Weissinger, Florian
    JOURNAL OF MEDICAL CASE REPORTS, 2023, 17 (01)
  • [5] Targeting the Fibroblast Growth Factor Receptor (FGFR) in Advanced Cholangiocarcinoma: Clinical Trial Progress and Future Considerations
    Lee, Patrick C.
    Hendifar, Andrew
    Osipov, Arsen
    Cho, May
    Li, Daneng
    Gong, Jun
    CANCERS, 2021, 13 (07)
  • [6] Fibroblast growth factor receptor (FGFR) inhibitors in cholangiocarcinoma: current status, insight on resistance mechanisms and toxicity management
    Chakrabarti, Sakti
    Finnes, Heidi D.
    Mahipal, Amit
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2022, 18 (01) : 85 - 98
  • [7] Fibroblast growth factor receptor 2 (FGFR2) fusions in Japanese patients with intrahepatic cholangiocarcinoma
    Tsujie, Masanori
    Iwai, Tomohisa
    Kubo, Shoji
    Ura, Takashi
    Hatano, Etsuro
    Sakai, Daisuke
    Takeda, Yutaka
    Kaibori, Masaki
    Kobayashi, Tomoe
    Katanuma, Akio
    Katayose, Yu
    Fukase, Koji
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (06) : 911 - 917
  • [8] The beginning of the era of precision medicine for gastric cancer with fibroblast growth factor receptor 2 aberration
    Ooki, Akira
    Yamaguchi, Kensei
    GASTRIC CANCER, 2021, 24 (06) : 1169 - 1183
  • [9] Ocular toxicities of fibroblast growth factor receptor inhibitors: A review
    Hsu, Jerry
    Francis, Jasmine H.
    Ahmad, Sumayya
    SURVEY OF OPHTHALMOLOGY, 2024, 69 (01) : 34 - 41
  • [10] New Era of Immune-Based Therapy in Intrahepatic Cholangiocarcinoma
    Kawamura, Etsushi
    Matsubara, Tsutomu
    Kawada, Norifumi
    CANCERS, 2023, 15 (15)
12345